Cancer breakthroughs surge, but trials and novel therapies stay out of reach for many. See how community care, policy, and design can close gaps.
May 2026
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
2
Considering Immunotherapy Rechallenge and TILs for Recurrent Mucosal Melanoma
3
B7-H3–Targeted ADC Risvutatug Rezetecan Extends Survival in Small Cell Lung Cancer
4
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Tumors
5